Main Article

Genomic Health (Redwood City, CA) has signed a national contract with Aetna (Hartford, CT) for Oncotype DX, the company’s test that quantifies the likelihood of breast cancer recurrence and predicts the likelihood of chemotherapy benefit for many early-stage breast cancer patients. The agreement with Aetna, which has more than 15 million health plan members, establishes payment rates across all of Aetna’s plans for members with early-stage breast cancer. Coverage for the test began late last year.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

January 2007 - Table of Contents

LIR January 2007 (full PDF issue)

Competitive Bidding Demo in Holding Pattern Awaiting OMB’s OK

Sonic to Acquire American Esoteric Laboratories for $180M

LabCorp Buys Kansas Lab

What Does ’07 Hold for LabCorp? LIR’s Interview With New CEO Dave King

Lab Industry Awaits First Domino of Competitive Bidding Project to Tip

Spotlight on Pap Testing: Monolayer Testing to Take 100% of Market in ’07?

BD Closes on $350m TriPath Acquisition

Luminex to Buy Tm Bioscience for $37.9M

Aetna Contracts With Genomic Health for Oncotype DX

Lab Stocks Rise 4%; Clarient and Genomic Health Soar 27%

Integrating MDx Conference